Cramer: Promising data from coronavirus drug trial ‘beginning of the end of the true nightmare’

Investing

Jim Cramer

Scott Mlyn | CNBC

CNBC’s Jim Cramer said Wednesday that positive news from Gilead Sciences about a potential treatment for the coronavirus marked a turning point in the fight against Covid-19.

“What I regard this as is the beginning of the end of the true nightmare, which is that it’s a death sentence,” Cramer said on “Squawk Box.”

U.S. stocks soared on Wednesday after Gilead indicated it was seeing positive, preliminary signs about the effectiveness of its antiviral remdesivir in treating coronavirus patients.

Cramer has been hopeful about remdesivir as a possible treatment.

Last week, the “Mad Money” host said, he believes that scientists testing treatments for the coronavirus will succeed in getting patients “out of the hospital faster” and reducing “death sentence” concerns.

On Thursday, Cramer said at the time, “I do feel better about what Gilead is doing.”

Articles You May Like

Wall Street analysts tout our 2 cybersecurity stocks ahead of quarterly earnings
Budget travel icon Spirit Airlines files for bankruptcy protection after mounting losses
California Ended Its Medicaid Long-Term Care Asset Test. What Happened?
Intuit shares drop as quarterly forecast misses estimates due to delayed revenue
Some market experts are talking about ‘animal spirits.’ Here’s what that means when it comes to investing

Leave a Reply

Your email address will not be published. Required fields are marked *